Ashkan Shoamanesh1, Sarah R Preis2, Alexa S Beiser2, Carlos S Kase2, Philip A Wolf2, Ramachandran S Vasan2, Emelia J Benjamin2, Sudha Seshadri2, Jose R Romero2. 1. From the McMaster University and Population Health Research Institute (A.S.), Hamilton, Canada; Boston University School of Public Health (S.R.P., A.S.B., E.J.B.), Boston; and Boston University School of Medicine (A.S., A.S.B., C.S.K., P.A.W., R.S.V., E.J.B., S.S., J.R.R.), Boston, MA. ashkan.shoamanesh@phri.ca. 2. From the McMaster University and Population Health Research Institute (A.S.), Hamilton, Canada; Boston University School of Public Health (S.R.P., A.S.B., E.J.B.), Boston; and Boston University School of Medicine (A.S., A.S.B., C.S.K., P.A.W., R.S.V., E.J.B., S.S., J.R.R.), Boston, MA.
Abstract
OBJECTIVE: We related a panel of inflammatory biomarkers to risk of incident ischemic stroke (IIS) in a community-dwelling sample. METHODS: Stroke-free Framingham offspring attending examination cycle 7 (1998-2001) had 15 circulating inflammatory biomarkers measured. Cox proportional hazard models were used to calculate the hazard ratios (HRs) of IIS per SD increment of each biomarker. Model 1 included age and sex. Model 2 additionally adjusted for systolic blood pressure, hypertension treatment, current smoking, diabetes, cardiovascular disease, and atrial fibrillation. The continuous net reclassification improvement was used to assess the improvement in IIS risk prediction of statistically significant biomarkers from our main analysis over traditional stroke risk factors. RESULTS: In 3,224 participants (mean age 61 ± 9 years, 54% women), 98 experienced IIS (mean follow-up of 9.8 [±2.2] years). In model 1, ln-C-reactive protein (ln-CRP) (HR 1.28, 95% confidence interval [CI] 1.04-1.56), ln-tumor necrosis factor receptor 2 (ln-TNFR2) (HR 1.33, 95% CI 1.09-1.63), ln-total homocysteine (ln-tHcy) (HR 1.32, 95% CI 1.11-1.58), and vascular endothelial growth factor (VEGF) (HR 1.25, 95% CI 1.07-1.46) were associated with risk of IIS. All associations, except for ln-CRP, remained significant in model 2 (ln-TNFR2: HR 1.24, 95% CI 1.02-1.51; ln-tHcy: HR 1.20, 95% CI 1.01-1.43; and VEGF: HR 1.21, 95% CI 1.04-1.42). The addition of these 4 biomarkers to the clinical Framingham Stroke Risk Profile score improved stroke risk prediction (net reclassification improvement: 0.34, 0.12-0.57; p < 0.05). CONCLUSIONS: Higher levels of 4 biomarkers-CRP, tHcy, TNFR2, and VEGF-increased risk of IIS and improved the predictive ability of the Framingham Stroke Risk Profile score. Further research is warranted to explore their role as potential therapeutic targets.
OBJECTIVE: We related a panel of inflammatory biomarkers to risk of incident ischemic stroke (IIS) in a community-dwelling sample. METHODS: Stroke-free Framingham offspring attending examination cycle 7 (1998-2001) had 15 circulating inflammatory biomarkers measured. Cox proportional hazard models were used to calculate the hazard ratios (HRs) of IIS per SD increment of each biomarker. Model 1 included age and sex. Model 2 additionally adjusted for systolic blood pressure, hypertension treatment, current smoking, diabetes, cardiovascular disease, and atrial fibrillation. The continuous net reclassification improvement was used to assess the improvement in IIS risk prediction of statistically significant biomarkers from our main analysis over traditional stroke risk factors. RESULTS: In 3,224 participants (mean age 61 ± 9 years, 54% women), 98 experienced IIS (mean follow-up of 9.8 [±2.2] years). In model 1, ln-C-reactive protein (ln-CRP) (HR 1.28, 95% confidence interval [CI] 1.04-1.56), ln-tumor necrosis factor receptor 2 (ln-TNFR2) (HR 1.33, 95% CI 1.09-1.63), ln-total homocysteine (ln-tHcy) (HR 1.32, 95% CI 1.11-1.58), and vascular endothelial growth factor (VEGF) (HR 1.25, 95% CI 1.07-1.46) were associated with risk of IIS. All associations, except for ln-CRP, remained significant in model 2 (ln-TNFR2: HR 1.24, 95% CI 1.02-1.51; ln-tHcy: HR 1.20, 95% CI 1.01-1.43; and VEGF: HR 1.21, 95% CI 1.04-1.42). The addition of these 4 biomarkers to the clinical Framingham Stroke Risk Profile score improved stroke risk prediction (net reclassification improvement: 0.34, 0.12-0.57; p < 0.05). CONCLUSIONS: Higher levels of 4 biomarkers-CRP, tHcy, TNFR2, and VEGF-increased risk of IIS and improved the predictive ability of the Framingham Stroke Risk Profile score. Further research is warranted to explore their role as potential therapeutic targets.
Authors: Androniki Bili; Xiaoqin Tang; Shruthi Pranesh; Rasa Bozaite; Stephanie J Morris; Jana L Antohe; H Lester Kirchner; Mary Chester M Wasko Journal: Arthritis Care Res (Hoboken) Date: 2014-03 Impact factor: 4.794
Authors: Rodica E Petrea; Alexa S Beiser; Sudha Seshadri; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf Journal: Stroke Date: 2009-02-10 Impact factor: 7.914
Authors: Ashkan Shoamanesh; Sarah R Preis; Alexa S Beiser; Ramachandran S Vasan; Emelia J Benjamin; Carlos S Kase; Philip A Wolf; Charles DeCarli; Jose R Romero; Sudha Seshadri Journal: Neurology Date: 2015-01-28 Impact factor: 9.910
Authors: Stephen R Williams; Fang-Chi Hsu; Keith L Keene; Wei-Min Chen; Sarah Nelson; Andrew M Southerland; Ebony B Madden; Bruce Coull; Stephanie M Gogarten; Karen L Furie; Godfrey Dzhivhuho; Joe L Rowles; Prachi Mehndiratta; Rainer Malik; Josée Dupuis; Honghuang Lin; Sudha Seshadri; Stephen S Rich; Michèle M Sale; Bradford B Worrall Journal: Neurology Date: 2015-12-30 Impact factor: 9.910
Authors: Robert J Campbell; Chaim M Bell; J Michael Paterson; Susan E Bronskill; Rahim Moineddin; Marlo Whitehead; Sudeep S Gill Journal: Ophthalmology Date: 2012-06-19 Impact factor: 12.079
Authors: Christopher R Kelly; Giora Weisz; Akiko Maehara; Gary S Mintz; Roxana Mehran; Alexandra J Lansky; Helen Parise; Bernard de Bruyne; Patrick W Serruys; Gregg W Stone Journal: Am J Cardiol Date: 2014-05-16 Impact factor: 2.778
Authors: Aleksandra Pikula; Alexa S Beiser; Tai C Chen; Sarah R Preis; Demetrios Vorgias; Charles DeCarli; Rhoda Au; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2013-08-08 Impact factor: 7.914
Authors: Lindsay M Miller; Nancy S Jenny; Andreea M Rawlings; Alice M Arnold; Annette L Fitzpatrick; Oscar L Lopez; Michelle C Odden Journal: J Gerontol A Biol Sci Med Sci Date: 2020-07-13 Impact factor: 6.053
Authors: Charlotte Andersson; Andrew D Johnson; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan Journal: Nat Rev Cardiol Date: 2019-11 Impact factor: 32.419
Authors: Marios K Georgakis; Rainer Malik; Harry Björkbacka; Tiberiu Alexandru Pana; Serkalem Demissie; Colby Ayers; Mohamed A Elhadad; Myriam Fornage; Alexa S Beiser; Emelia J Benjamin; S Matthijs Boekholdt; Gunnar Engström; Christian Herder; Ron C Hoogeveen; Wolfgang Koenig; Olle Melander; Marju Orho-Melander; Alexandru Schiopu; Martin Söderholm; Nick Wareham; Christie M Ballantyne; Annette Peters; Sudha Seshadri; Phyo K Myint; Jan Nilsson; James A de Lemos; Martin Dichgans Journal: Circ Res Date: 2019-09-03 Impact factor: 17.367
Authors: Wenjun Deng; David McMullin; Ignacio Inglessis-Azuaje; Joseph J Locascio; Igor F Palacios; Ferdinando S Buonanno; Eng H Lo; MingMing Ning Journal: Neurology Date: 2021-05-13 Impact factor: 11.800